Sridhar, Sriram
Liu, Hao
Pham, Tuyet-Hang
Damera, Gautam
Newbold, Paul
Article History
Received: 28 June 2018
Accepted: 19 December 2018
First Online: 18 January 2019
Ethics approval and consent to participate
: Protocols of both studies included in this analysis were developed by the chief investigators and MedImmune and were approved by the institutional review board at each study site. Participants provided written informed consent, and the studies were performed in accordance with the Declaration of Helsinki.
: Not applicable.
: All authors are employees of AstraZeneca/MedImmune LLC, the manufacturer of benralizumab.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.